CHARACTERISTICS OF TREATMENT OF PATIENTS WITH ACUTE AND CHRONIC LARYNGITIS DEPENDING ON RESULTS OF BACTERIOLOGICAL EXAMINATION OF LARYNX MICROFLORA

This paper describes study of larynx microflora in patients with acute laryngtis and exacerbations of chronic laryngitis. Therapeutic algorithm based on bacteriologic examination data was developed reduce. New algorithm helps reduce sickness terms and to decrease prevalence of desease.
123 patients of age from 18 to 60 were under observation: 43 patients with acute laryngitis and 80 patients with exacerbation of chronic laryngitis. 22 patients with acute laryngitis and 58 patients with exacerbation of chronic laryngitis underwent etiotropic treatment with antibiotics. The group of comparison with acute laryngitis (21 patients) and chronic laryngitis (22 patients) received treatment according to the conventional scheme.
Bacteriologic examination of larynx mucous, clinical study and functional voice test (time of maximum vowels phonation) before and after treatment were carried out.
As a result of the research it was established that the most common causative agent of acute and chronic inflammatory larynx diseases is S. aureus as a mono culture or combined with other bacterial associations (S. аnhemolyticus, Str. viridans etc.).
After the end of antibacterial therapy we found symptoms as hoarseness, irritation, dry laryngopharynx, hyperemia and swelling of larynx mucous reduced eather in new treatment group than controlled group. Time of maximum vowels phonation (in seconds) also increased significantly.
Sickness terms after prescription of new treatment was shorter than in comparison groups: (10.9 ± 7.9) days for acute laryngitis and (12.6 ± 7.3) days for chronic laryngitis respectively. Health index was 20.8 and 19.5% respectively.

1. Demchenko Ye.V. Ivanchenko G.F., Novakovsky D.L. Modern aspects of clinical and laboratory diagnosis and treatment of chronic hyperplastic laryngitis. Quality of Life. Medicine, 2007, pp. 35–38 (in Russian).

2. Kunel'skaya N.L., Gurov A.V. The possibility of using azalides in ENT practice. Medical Business, 2010, no. 4, 7 p. (in Russian).

3. Morozov S.V. Immunomodulatory therapy for chronic tonsillitis. The Attending Physician, 2002, no. 11 (in Russian).

4. Osipenko Ye.V. Anti-inflammatory therapy in the treatment of patients with chronic laryngitis. Vestnik Otorinolaringologii, 2009, no. 4, pp. 63–65 (in Russian).

5. Ryabova M.A., Nemykh O.V. Chronic laryngitis: principles of the pathogenetic treatment. St. Petersburg, 2010. 139 p. (in Russian).

6. Vasilenko Yu.S. Voice. Foneatric aspects. Moscow, Dipak Publ., 2002. 480 p. (in Russian).

7. Gurov A.V. Prolonged form of clarithromycin in the treatment of acute purulent-inflammatory diseases of upper respiratory tract. Russian Medical Journal, 2008, vol. 16, no. 22 (in Russian).

8. Svistushkin V.M. Empirical antibiotic therapy in acute inflammatory diseases of the upper respiratory tract. Russian Medical Journal, 2005, vol. 13, no. 4 (in Russian).

9. Sturov N.V., Ushkalova Ye.A. Efficacy and safety of azithromycin in the treatment of upper respiratory tract in fections. Farmateka, 2008, no. 4, pp. 65–68 (in Russian).

10. Lazareva Ye.B. Bacteriophages and the pectin in the correction of microbiocenosis disorders in purulent inflammatory processes. Autor. dis. Dr. med. sci. Moscow, 2007. 13 p. (in Russian).

11. Fattakhov B.T. Use of eubacteria in the treatment and prevention of wound infection eyes. Avtor. dis. Cand. med. sci. Ufa, 1999. 13 p. (in Russian).

12. Esposito S., Bosis S., Begliatti E. et al. Acute tonsillopharyngitis associated with atypical bacterial infection in children: natural history and impact of macrolide therapy. Clin. Infect. Dis., 2006, 43 (2), pp. 206–209.

13. 13. Sunagar R., Patil S.A., Chandrakanth R.K. Bacteriophage therapy for Staphylococcus aureus bacteremia in streptozotocin-induced diabetic mice. Res. Microbiol., 2010, Dec., 161 (10), pp. 854–860. Epub 2010 Sep.

14. Daniel A., Euler C., Collin M., Chahales P., Gorelick K.J., Fischetti V.A. Antimicrob Agents Chemother. Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents. Chemother., 2010, Apr. 54 (4), pp. 1603–1612. Epub 2010 Jan 19.